MoonLake's Sonelokimab Receives FDA Fast Track Status for Rare Inflammatory Disorder Treatment

MoonLake Immunotherapeutics' sonelokimab has received Fast Track status from the US FDA for treating moderate-to-severe palmoplantar pustulosis. The decision was based on results from the ongoing phase 2 LEDA trial. This designation is intended to expedite the development and review process for rare and serious conditions.